These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
563 related articles for article (PubMed ID: 6713400)
21. Induction of antiproliferation and apoptosis in estrogen receptor negative MDA-231 human breast cancer cells by mifepristone and 4-hydroxytamoxifen combination therapy: a role for TGFbeta1. Liang Y; Hou M; Kallab AM; Barrett JT; El Etreby F; Schoenlein PV Int J Oncol; 2003 Aug; 23(2):369-80. PubMed ID: 12851686 [TBL] [Abstract][Full Text] [Related]
22. Antiestrogenic activity of DP-TAT-59, an active metabolite of TAT-59 against human breast cancer. Toko T; Shibata J; Nukatsuka M; Yamada Y Cancer Chemother Pharmacol; 1997; 39(5):390-8. PubMed ID: 9054952 [TBL] [Abstract][Full Text] [Related]
23. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo. Dardes RC; O'Regan RM; Gajdos C; Robinson SP; Bentrem D; De Los Reyes A; Jordan VC Clin Cancer Res; 2002 Jun; 8(6):1995-2001. PubMed ID: 12060645 [TBL] [Abstract][Full Text] [Related]
24. Antiestrogen pharmacology and mechanism of action. Katzenellenbogen BS; Miller MA; Eckert RL; Sudo K J Steroid Biochem; 1983 Jul; 19(1A):59-68. PubMed ID: 6887873 [TBL] [Abstract][Full Text] [Related]
25. Antiestrogens increase protein tyrosine phosphatase activity in human breast cancer cells. Freiss G; Vignon F Mol Endocrinol; 1994 Oct; 8(10):1389-96. PubMed ID: 7854356 [TBL] [Abstract][Full Text] [Related]
26. Preclinical rationale for combined use of endocrine therapy and 5-fluorouracil but neither doxorubicin nor paclitaxel in the treatment of endocrine-responsive breast cancer. Kurebayashi J; Nukatsuka M; Sonoo H; Uchida J; Kiniwa M Cancer Chemother Pharmacol; 2010 Jan; 65(2):219-25. PubMed ID: 19455332 [TBL] [Abstract][Full Text] [Related]
27. Synthetic antiestrogens modulate induction of pS2 and cathepsin-D messenger ribonucleic acid by growth factors and adenosine 3',5'-monophosphate in MCF7 cells. Chalbos D; Philips A; Galtier F; Rochefort H Endocrinology; 1993 Aug; 133(2):571-6. PubMed ID: 8344199 [TBL] [Abstract][Full Text] [Related]
28. Antiestrogen action in breast cancer cells: modulation of proliferation and protein synthesis, and interaction with estrogen receptors and additional antiestrogen binding sites. Katzenellenbogen BS; Miller MA; Mullick A; Sheen YY Breast Cancer Res Treat; 1985; 5(3):231-43. PubMed ID: 4027393 [TBL] [Abstract][Full Text] [Related]
29. Differential regulation of growth and invasiveness of MCF-7 breast cancer cells by antiestrogens. Thompson EW; Reich R; Shima TB; Albini A; Graf J; Martin GR; Dickson RB; Lippman ME Cancer Res; 1988 Dec; 48(23):6764-8. PubMed ID: 2846159 [TBL] [Abstract][Full Text] [Related]
30. A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analog. Catherino WH; Wolf DM; Jordan VC Mol Endocrinol; 1995 Aug; 9(8):1053-63. PubMed ID: 7476979 [TBL] [Abstract][Full Text] [Related]
31. A metastatic breast tumor cell line, GI-101A, is estrogen receptor positive and responsive to estrogen but resistant to tamoxifen. Morrissey JJ; Raney S Cell Biol Int; 1998; 22(6):413-9. PubMed ID: 10328849 [TBL] [Abstract][Full Text] [Related]
32. Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Lim YC; Desta Z; Flockhart DA; Skaar TC Cancer Chemother Pharmacol; 2005 May; 55(5):471-8. PubMed ID: 15685451 [TBL] [Abstract][Full Text] [Related]
33. Accumulation of a non-binding form of estrogen receptor in MCF-7 cells under hydroxytamoxifen treatment. Leclercq G; Legros N; Piccart MJ J Steroid Biochem Mol Biol; 1992 Mar; 41(3-8):545-52. PubMed ID: 1562525 [TBL] [Abstract][Full Text] [Related]
34. An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol. Jiang SY; Wolf DM; Yingling JM; Chang C; Jordan VC Mol Cell Endocrinol; 1992 Dec; 90(1):77-86. PubMed ID: 1301400 [TBL] [Abstract][Full Text] [Related]
35. Structural requirements for the pharmacological activity of nonsteroidal antiestrogens in vitro. Jordan VC; Lieberman ME; Cormier E; Koch R; Bagley JR; Ruenitz PC Mol Pharmacol; 1984 Sep; 26(2):272-8. PubMed ID: 6482874 [TBL] [Abstract][Full Text] [Related]
36. Effects of serum and insulin on the sensitivity of the human breast cancer cell line MCF-7 to estrogen and antiestrogens. Butler WB; Kelsey WH; Goran N Cancer Res; 1981 Jan; 41(1):82-8. PubMed ID: 7004631 [TBL] [Abstract][Full Text] [Related]
37. Regulation of parathyroid hormone-related protein expression in MCF-7 breast carcinoma cells by estrogen and antiestrogens. Funk JL; Wei H Biochem Biophys Res Commun; 1998 Oct; 251(3):849-54. PubMed ID: 9790998 [TBL] [Abstract][Full Text] [Related]
38. Steroidal and nonsteroidal antiestrogens in breast cancer cells in culture. Rochefort H; Bardon S; Chalbos D; Vignon F J Steroid Biochem; 1984 Jan; 20(1):105-10. PubMed ID: 6368983 [TBL] [Abstract][Full Text] [Related]
40. Genetic instability and the development of steroid hormone insensitivity in cultured T 47D human breast cancer cells. Reddel RR; Alexander IE; Koga M; Shine J; Sutherland RL Cancer Res; 1988 Aug; 48(15):4340-7. PubMed ID: 3390830 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]